Skip to main content

Table 2 Adverse events observed in untreated and drug-treated patients with borderline or less severe PH

From: Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

  Untreated borderline or less severe PH Drug-treated borderline or less severe PH
Exacerbation of dyspnea 7 3
Time to exacerbation of dyspnea (mean ± SD) (days) 152.00 ± 89.94 259.00 ± 49.37
Increase of the O2 dose 5 2
Time to O2 dose increase (mean ± SE) (days) 199.00 ± 132.90, 335.00 ± 182.43
Decrease of the O2 dose 0 1
Hospitalization (hospital-free survival) 8 (241.50 ± 192.24) 2 (239.002 ± 169.00)
Death (survival) 7 (309.29 ± 195.13) 1 (671)
Other adverse events 3a 6b
  1. a Gastrointestinal hemorrhage (n = 1), pneumonia (n = 1), and ileus (n = 1)
  2. b Pneumothorax (n = 3), CHF (n = 2), and liver dysfunction (n = 1)